Is Aubagio (teriflunomide) widely available worldwide?
Aubagio (teriflunomide) is marketed in multiple countries as a disease-modifying treatment for relapsing forms of multiple sclerosis, but the level of availability can vary by market. Some regions carry only the brand product, while others also have generic teriflunomide, which can make access broader and cheaper.
Which countries/regions tend to have it?
Availability is typically strongest in markets where multiple sclerosis therapies are routinely stocked and reimbursed through national formularies or private channels (for example, parts of North America and Europe). Access can be more limited in countries without local marketing agreements or where neurologists rely on imported product.
Does generic teriflunomide make it “more widely available”?
In many markets, generic versions of teriflunomide expand access compared with the brand-only situation. If a country has generic approval and local distribution, pharmacies may substitute generics for Aubagio, making supply more consistent and often reducing cost.
Why might patients find Aubagio unavailable in some places?
Even when a drug is approved in a country, real-world availability can be affected by:
- distribution and wholesaler coverage
- insurance or reimbursement rules
- formulary placement or prior authorization requirements
- manufacturing or supply interruptions
How can you check whether it’s available where you live?
Drug availability is easiest to confirm using local options:
- ask a local neurologist or MS clinic whether they prescribe Aubagio or generic teriflunomide there
- check pharmacy inventory through local distributors
- verify the product’s approved status in your country’s medicines agency and whether generics are listed
If you tell me your country (or the country you’re trying to get it in), I can help you narrow down whether it’s typically available as Aubagio versus generic teriflunomide.
Sources